TrialNature communications2025

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial.

Dongliang Bian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.